What did Rua Bioscience Limited announce?

Rua Bioscience Limited (NZX: RUA) filed “Rua announces detail of rights offer” with NZX on 22 September 2026, as a listing change announcement.

From the announcement:“Capital raise – Pro-rata renounceable Rights Offer Rua is today announcing an offer to existing shareholders an opportunity to participate in our renoucenable rights issue of 1 New Shares for every 3 Existing Shares to raise up to $2.8million (“ Rights Offer”).”
When was it filed?
22 September 2026
Where is the original?
NZX announcement
Rua Bioscience Limited logo

Rua announces detail of rights offer

Listing Change22 September 2026RUAHealthcare

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE

NZX Limited

Wellington


22 September 2026


Capital raise – Pro-rata renounceable Rights Offer


Rua is today announcing an offer to existing shareholders an opportunity to participate in

our renoucenable rights issue of 1 New Shares for every 3 Existing Shares to raise up to

$2.8million (“

Rights Offer”).

FY26 marked an important period of meaningful commercial progress for Rua. Our export-

led strategy is delivering tangible results, with revenue increasing to $2.9 million, compared

with $1.9 million in FY25, alongside continued expansion across our key international

markets. We have strengthened our position in established markets and opened important

new growth pathways, demonstrating the increasing international demand for high-

quality New Zealand-grown medicinal cannabis.

Most significantly, towards the end of FY26, Rua secured its largest export agreement to

date, signing a major UK sales and distribution agreement with one of the world’s leading

medical cannabis companies. Expected to generate an estimated NZ$10 million in revenue

over its initial two-year term.


OFFER ANNOUNCEMENT

$0.3m

$1.9m

$2.9m

FY24FY25FY26


PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

This new export agreement represents more than a future opportunity. It is an important

commercial validation of the strategy Rua has been pursuing: building an export-led

business founded on differentiated New Zealand genetics, high-quality cultivation and

access to established international markets.

The next phase for Rua is to convert this commercial momentum into sustained revenue

growth. Doing so requires investment in inventory and working capital to meet increasing

customer demand. The capital sought through this Offer will therefore primarily support

the fulfilment of customer demand and the conversion of available market opportunities

into revenue and margin, enabling Rua to maximise the value of the opportunities now

available to it.

Rua intends to use the cash raised through the Rights Offer to fund working capital and

marketing activities to support our growth opportunities, particularly in the United

Kingdom, alongside our other key international markets of Germany, Australia, Czechia

and Canada.

If fully subscribed, the Rights Offer, together with the expected proceeds from the sale of

the Gisborne manufacturing facility, is expected to provide the funding required to take

the business to a self-sustaining position.

The issue price under the Rights Offer is $0.025 per share, representing a 32 % discount to

the 20-day volume weighted average price of Rua shares up to 17 September 2026. Rua

notes that this price reflects that the Rights Offer is being offered to existing eligible

shareholders resident in New Zealand or Australia.

Eligible shareholders who take up their rights in full may also apply for any number of

additional shares at the same issue price under the Oversubscription Facility.

The key dates for the Rights Offer are as follows:

Announcement of the Offer Tu e s d a y, 2 2 September 2026

Rights Trading Opens Monday, 2 8 September 2026

Record Date 5pm, Tu e s d a y, 2 9 September 2026

Opening Date of the Offer 2pm, Wednesday, 30 September 2026

Rights Trading Closes Friday, 9 October 2026

Closing Date of the Offer Thursday, 15 October 2026

Announcement of Results of the Offer Tu e s d a y, 2 0 October 2026

Issue Date Wednesday, 21 October 2026

Quotation of New Shares on NZX Main

Board

Wednesday, 21 October 2026



PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com


Further Information

Rua has lodged an Investor Presentation and Offer Document with the NZX today. Both

documents contain important information including the terms of the Rights Offer and key

risk factors and Rua encourages shareholders to read them in full. The Offer Document

and Investor Presentation along with other important information relating to the Rights

Offer will be available on the website established for the Rights Offer at

www.shareoffer.co.nz/rua.

Shareholders with any questions about the Rights Offer, please email

rua@computershare.co.nz or call the Computershare Investor Information Line between

8:30am to 5.00pm Monday to Friday (NZDT) (excluding public holidays):

For New Zealand shareholders

0800 650 034 - toll free within New Zealand

+64 9 488 8793


For Australian shareholders

1800 501 366 - toll free within Australia

+61 3 9415 4083



Or alternatively, contact your broker or your financial, investment or other professional

adviser.

A copy of the following documents also accompany this announcement:

• Offer Document

• Investor Presentation

• Corporate Action Notice

• Cleansing Notice


ENDS  

 

The person who authorised this announcement:


Paul Naske

Chief Executive Officer

paul.naske@ruabio.com

+64 21 445154

---

Rua Bioscience Limited
Renounceable Rights Offer



Offer Document



1 for 3 renounceable rights offer of ordinary shares

Dated 22 September 2026

Not for release to U.S. wire services or distribution in the United States.


This is an important document. You should read the whole document before deciding what action to take with your

Rights. If you have any doubts as to what you should do, please consult your broker, financial, investment, legal or other

professional advisor. This document may not be distributed outside New Zealand or Australia.

Important Information
General information

This document has been prepared by Rua Bioscience

Limited (“Rua”) in connection with a 1 for 3 renounceable

rights offer of New Shares to Eligible Shareholders

(“Offer”). The Offer is made under the exclusion in clause

19 of Schedule 1 of the Financial Markets Conduct Act

2013 (the “FMCA”).


This document is not a product disclosure statement for

the purposes of the FMCA and does not contain all of the

information that an investor would find in a product

disclosure statement, or which may be required in order

to make an informed investment decision about the Offer

or Rua.


Further Important Information

A presentation providing further important information in

relation to Rua and the Offer has been published by Rua

on 22 September 2026 (the “Investor Presentation”). A

copy of the Investor Presentation and other important

information released on 22 September 2026, as well as

other publicly available information referred to in this

document, are available at www.nzx.com under the ticker

code “RUA”.


The Investor Presentation includes details of the rationale

for the Offer. It also provides a general trading update and

explains in more detail the expected impact of the Offer,

including a non-exhaustive summary of certain key risks

associated with Rua and the Offer.


You should read the Investor Presentation in full, as it

contains important information to assist you in making an

investment decision in respect of the Offer. In particular,

you should read and consider Appendix B of the Investor

Presentation detailing the risks before making an

investment decision.


Additional information available

Rua is subject to continuous disclosure obligations under

the NZX Main Board Listing Rules. Further information

relating to the Offer can also be found in Rua’s recent

market announcements and its most recent audited

consolidated financial statements for the 12 month

period ended 30 June 2026, which can be found in Rua’s

2026 Annual Report which is accessible online at

www.nzx.com under the ticker code RUA and on Rua’s

website at https://www.ruabio.com/investors.


Rua may, during the period of the Offer, make additional

releases to the NZX. To the maximum extent permitted by

law, no release by Rua to the NZX will permit an applicant

under the Offer to withdraw any previously submitted

application without Rua’s prior consent.

We encourage you to read this document and to seek

investment advice from a suitably qualified professional

adviser before you consider investing.



Offering restrictions

No action has been taken to permit a public offering of

the New Shares in any jurisdiction outside New Zealand,

or Australia. The Offer may also be made and accepted in

such other place where a Shareholder satisfies Rua that

the Offer can lawfully be made and accepted in that

place.


However, Shareholders in the United States are not

eligible to participate in the Offer. Similarly, Shareholders

(including trustees, Custodians and nominees) who hold

Shares on behalf of persons in the United States, or who

are acting for the account or benefit of persons in the

United States, are not eligible to participate in the Offer

on behalf of those persons.


The distribution of this document (including an electronic

copy) in a jurisdiction outside the Offer Jurisdictions may

be restricted by law, and persons who come into

possession of it (including trustees, Custodians or

nominees) should seek advice on and observe any such

restrictions. In particular, no person may subscribe for,

purchase, offer, sell, distribute or deliver New Shares, or

be in possession of, or distribute to any other person, any

offering material or any documents in connection with the

Offer or the New Shares, in any jurisdiction unless in

compliance with all applicable laws and regulations.

The New Shares to be offered and sold under this Offer

have not been, and will not be, registered under the U.S.

Securities Act of 1933, as amended (the U.S. Securities

Act), or the securities laws of any state or other

jurisdiction of the United States, and may not be offered

or sold in the United States or to any person acting for the

account or benefit of a person in the United States except

in accordance with an available exemption from, or in a

transaction not subject to, the registration requirements

of the U.S. Securities Act and any other applicable

securities laws.


Australia

This document and the offer of New Shares under the

Offer are being made in Australia in reliance on the

Australian Securities and Investments Commission

Corporations (Foreign Rights Issues) Instrument 2015/356

or otherwise to persons to whom the Offer can be made

without a formal disclosure document under Chapter 6D

of the Corporations Act 2001 (Cth) (the “Corporations

Act”).

This document (whether alone or together with the

Investor Presentation) is not a prospectus, product

disclosure statement or any other formal disclosure

document for the purposes of Australian law or the

Corporations Act and is not required to, and does not,

contain all the information which would be required in a

disclosure document under Australian law or the

Corporations Act. It contains references to dollar
amounts which are not Australian dollars, may contain

financial information which is not prepared in accordance

with Australian law or practices, may not address risks

associated with investment in foreign currency

denominated investments and does not address

Australian tax issues.

Rua is a company which is incorporated in New Zealand

and the relationship between it and investors will be

largely governed by New Zealand law. This document has

not been, and will not be, lodged or registered with the

Australian Securities and Investments Commission or the

Australian Securities Exchange and Rua is not subject to

the continuous disclosure requirements that apply in

Australia.

Eligible Shareholders and other investors should not

construe anything in this document as legal, business or

tax advice nor as financial product advice for the

purposes of Chapter 7 of the Corporations Act.

Pursuant to the ASIC Corporations (Foreign Rights Issues)

Instrument 2015/356, Australian residents may also be

limited in the number of Additional New Shares they may

be allocated pursuant to the Oversubscription Facility if

and to the extent such allocation would result in more

than 10% of the maximum number of New Shares being

offered to Australian residents.


No guarantee

There is no guarantee that the Offer will proceed nor any

guarantees about the future performance of Rua or any

return on any investment made under this document.


Decision to participate in the Offer

The information in this document does not constitute

financial product advice or a recommendation to acquire

New Shares. This document has been prepared without

taking into account the investment objectives, financial,

or taxation situation or particular needs of any Eligible

Shareholder or other investor.

Before deciding whether to invest in New Shares,

you must make your own assessment of the risks

associated with an investment in Rua

(including the inherent uncertainties as to solvency and

the summary of key risks in Appendix B of the Investor

Presentation (“Key Risks”)), and consider whether such

an investment is suitable for you having regard to publicly

available information (including the Investor Presentation

and Rua’s other market releases lodged with the NZX),

your personal circumstances and following consultation

with a financial or other professional adviser. Please read

this document carefully and in full before making that

decision.


Forward looking statements

This document contains certain statements that relate to

the future. Such forward looking statements are not a

guarantee of future performance and involve known and

unknown risks, uncertainties, assumptions and other

factors, many of which are beyond the control of Rua, and

which may cause the actual results, performance or

achievements of Rua to differ materially from those

expressed or implied by such statements.

Under no circumstances should you regard the inclusion

of forward looking statements in this document as a

guarantee of future performance.

The statements, although made in good faith, involve

known and unknown risks, uncertainties and

assumptions, many of which are beyond Rua’s control.


Privacy

Any personal information provided by Eligible

Shareholders online will be held by Rua and/or

Computershare at the addresses set out in the Directory

at the back of this document. This information will be

used for the purposes of administering your investment in

Rua and will be disclosed to third parties only with your

consent or if required by law. Under the Privacy Act 2020

(New Zealand), you have the right to request access to,

and correction of, personal information held about you.


Dividend policy

The payment of dividends is at the discretion of the Board.

The Board has no present intention to make a distribution

for the foreseeable future. This policy may change from

time to time at the discretion of the Board in the future.


Enquiries

Enquiries about the Offer can be directed to an NZX Firm

or your financial or legal adviser. If you have any questions

about your Entitlement, or how to apply online, please

contact Computershare.


Times

All references to time in this document are to New

Zealand time.


Defined terms

Capitalised terms used in this document have the

specific meaning given to them in the Glossary at the

back of this document or in the relevant section of this

document.



Letter from the Chair


Dear Shareholders,

On behalf of the directors of Rua, we are pleased to offer Eligible Shareholders the opportunity to participate in our

renounceable rights issue of 1 New Share for every 3 Existing Shares held on the Record Date at an issue price of

$0.025 per New Share.

On Tuesday, 22 September, Rua released its 2026 Annual Report, which includes Rua’s audited consolidated financial

results for the 12-month period to 30 June 2026 (the “2026 Annual Report”).

A copy of the 2026 Annual Report, shareholder update and other announcements made by the company are available

at https://www.nzx.com/companies/RUA/announcements

FY26 marked an important period of meaningful commercial progress for Rua. Our export-led strategy is delivering

tangible results, with revenue increasing to $2.9 million, compared with $1.9 million in FY25, alongside continued

expansion across our key international markets. We have strengthened our position in established markets and opened

important new growth pathways, demonstrating the increasing international demand for high-quality New Zealand-

grown medicinal cannabis.

Most significantly, during the year Rua secured its largest export agreement to date, signing a major UK sales and

distribution agreement with one of the world’s leading medical cannabis companies, expected to generate NZ$10

million in revenue over its initial two-year term.

This new export agreement represents more than a future opportunity. It is an important commercial validation of the

strategy Rua has been pursuing: building an export-led business founded on differentiated New Zealand genetics, high-

quality cultivation and access to established international markets.

The next phase for Rua is to convert this commercial momentum into sustained revenue growth. Doing so requires

investment in inventory and working capital to meet increasing customer demand. The capital sought through this Offer

will therefore primarily support the fulfilment of customer demand and the conversion of available market

opportunities into revenue, enabling Rua to maximise the value of the opportunities now available to it.

Based on Rua’s current sales expectations for FY27, assuming sufficient funding is in place, and the expected costs of

delivering our global growth strategy, the target proceeds from the Offer - together with the anticipated proceeds from

the potential sale of the Gisborne manufacturing facility - are expected to provide the funding required to progress Rua

towards a self-sustaining position.

If sufficient funds are not raised under the Offer, or if the Gisborne manufacturing facility sale is further delayed, Rua

may need to reconsider its current strategy. This could constrain anticipated growth and/or require us to explore

alternative capital-raising options. It may also affect our ability to continue as a going concern. Under the Offer, Eligible

Shareholders who subscribe for their Entitlement in full may also apply for any number of Additional New Shares at the

same Issue Price under the Oversubscription Facility. Eligible Shareholders have until 5:00pm on 15 October 2026 to

apply under the Offer at the following link: www.shareoffer.co.nz/rua.

If you are a Custodian or hold your Shares in Rua through a Custodian (for example, Sharesies), please refer to

paragraphs 13 and 14 of the Terms and conditions section of this document.

Shareholders who choose not to take up their Entitlements may sell some or all of their Rights on the NZX Main Board

by instructing your broker or an NZX Firm. Rights trading will be available on NZX from 28 September until 9 October

2026. However, due to anticipated low liquidity and the likely low value of the Rights, it is highly uncertain whether there

will be sufficient liquidity to support any meaningful Rights trading. Shareholders who choose not to take up their

Entitlements will have their percentage shareholding diluted. The directors of Rua may also place any shortfall in the
Offer with new investors at the same price as the Issue Price and within 3 months of the close of the Offer in

accordance with the NZX Listing Rules.

This document should be read together with the Investor Presentation and other important information which is

available to Eligible Shareholders at www.shareoffer.co.nz/rua. These documents contain important information about

Rua and the risks associated with an investment in Rua. Before making your investment decision, I encourage you to

read these documents in full, and importantly, seek independent financial advice where further support is required.


Ngā Mihi,



Anna Stove

Chair

Key Terms of the Offer
The Offer

A pro-rata renounceable rights issue of 1 New Share for every 3 Existing Shares held on

the Record Date, with fractional Entitlements being rounded down to the nearest

share.

Eligible Shareholders Shareholders with registered addresses in the Offer Jurisdictions on the Record Date.

Issue Price $0.025 per New Share.

Offer Size Up to $2,828,681.

Rights

Eligible Shareholders may take up all or some or none of their Rights. Rights will be

quoted on the NZX Main Board so Eligible Shareholders may sell all or some of their

Rights on the NZX Main Board between 28 September 2026 and 9 October 2026.


Eligible Shareholders do not pay for the Rights themselves. Eligible Shareholders will

pay only for the New Shares issued to them if they choose to take up all or some of

their Rights.

Exercising Rights

purchased on the NZX

Rights purchased on the NZX may only be exercised by purchasers that meet eligibility

requirements. In particular, rights may not be exercised by purchasers that are in the

United States or who are acting for the account or benefit of persons in the United

States (to the extent such persons are acting for the account or benefit of persons in

the United States). Potential purchasers of Rights should familiarise themselves with

the requirements for exercise, which are set out in this document.

Oversubscriptions

If you accept your Entitlement in full, you may apply for any number of Additional New

Shares pursuant to the Oversubscription Facility.

Any Additional New Shares applied for under the Oversubscription Facility will be

issued at the issue price of $0.025.

Australian residents may however be limited in the number of Additional New Shares

they may be allocated pursuant to the Oversubscription Facility if and to the extent

such allocation would result in more than 10% of the maximum number of New Shares

being offered to Australian residents.

Maximum number of

New Shares being

offered

113,147,235 New Shares.


When to apply

Applications must be received by 5:00pm on the Closing Date (being Thursday, 15

October 2026, unless extended).

How to apply

Applications may be made online at www.shareoffer.co.nz/rua.

To complete an online application, you will be required to enter your CSN/Holder

number. Payment for applications must be made online by direct credit prior to the

Closing Date (5:00pm on Thursday, 15 October 2026, unless extended).

If you are a Custodian, please see paragraphs 13 and 14 in the Terms and conditions

section of this document.

If you hold your Shares through a Custodian, please provide your Custodian with your

instructions so that they may apply on your behalf in accordance with paragraphs 13

and 14 in the Terms and conditions section of this document.

No underwriting The Offer is not underwritten


While participation in the Offer is optional, if Eligible Shareholders choose not to take up their Entitlement, their

shareholdings in Rua will be diluted.

Important Dates
Announcement of the Offer Tuesday, 22 September 2026

Rights Trading Opens

(Rights trading commences on the NZX Main Board)

Monday, 28 September 2026

Record Date

(for determining eligibility to participate in the Offer and Entitlements)

5pm, Tuesday, 29 September 2026

Opening Date of the Offer

(including mailing/emailing of Offer documentation)

2pm, Wednesday, 30 September 2026

Rights Trading Closes

(Rights trading closes on the NZX Main Board at the close of trading)

Friday, 9 October 2026

Closing Date of the Offer

(being the date by which applications and payment must be received)

Thursday, 15 October, 2026

Announcement of Results of the Offer Tuesday, 20 October 2026

Issue Date

(for the allotment and issue of the New Shares)

Wednesday, 21 October 2026

Quotation of New Shares on NZX Main Board Wednesday, 21 October 2026

Holding Statements Dispatched Tuesday, 27 October 2026


These dates are subject to change and are indicative only. Rua reserves the right to amend this timetable (including by

extending the Closing Date) subject to applicable laws and the Listing Rules. Rua reserves the right to withdraw the

Offer and/or issue New Shares at any time before the Issue Date in its absolute discretion.

Actions to be taken by Eligible Shareholders
Available actions in respect of your Rights

If you are an Eligible Shareholder, you may take the following actions:

• take up all or some of your Rights; or

• take up all of your Rights and apply for Additional New Shares as a part of the Oversubscription Facility; or

• sell all or some of your Rights on the NZX Main Board; or

• take up some of your Rights, and sell all or some of the remaining balance on the NZX Main Board; or

• do nothing with all or some of your Rights.

Take up all or some of your rights

If you are an Eligible Shareholder and wish to take up all or some of your Rights, you can apply online at

www.shareoffer.co.nz/rua.

If you are a Custodian, please see paragraphs 13 and 14 in the Terms and Conditions section of this document.

If you hold your Shares through a Custodian, please provide your Custodian with your instructions so that they may

apply on your behalf in accordance with paragraphs 13 and 14 in the Terms and Conditions section of this document.

Apply for Additional New Shares as a part of the Oversubscription Facility

Eligible Shareholders who take up their Rights in full have the opportunity to apply for Additional New Shares as a part

of the Oversubscription Facility. To participate in the Oversubscription Facility you must:

a. take up your Rights in full as directed via the online application process; and

b. apply for New Shares under the Oversubscription Facility as directed via the online application process.

Sell your Rights

The Rights are renounceable. This enables Eligible Shareholders who do not wish to take up all or some of their

Entitlement to sell those Rights they have not taken up.

If you wish to sell all or some of your Rights, this can be effected on the NZX Main Board by instructing an NZX Firm to

sell all or some of your Rights. You will need to provide your Authorisation Code (FIN) and your Common Shareholder

Number (CSN) to the NZX Firm who you are instructing to sell your Rights. You may be required to pay brokerage in

respect of that sale. If you are not an NZX Shareholder and you wish to sell your Rights on the NZX Main Board, please

contact your broker or an NZX Firm.

Trading of Rights will commence on the NZX Main Board under the code “RUARC” on 28 September 2026 and will end at

the close of trading on 9 October 2026. Your Rights may be sold on the NZX Main Board between these dates.

Do Nothing

If you do nothing, your Rights will lapse. You will not be able to subscribe for any New Shares and your shareholding

percentage will be diluted by the issue of New Shares under the Offer.

Terms and Conditions
1. The Offer

The Offer is an offer of New Shares in Rua to Eligible

Shareholders under a pro-rata renounceable rights issue.

Under the Offer, Eligible Shareholders are entitled to

subscribe for 1 New Share for every 3 Existing Shares held

by them on the Record Date (with any fractional

Entitlements rounded down) and may also apply for

Additional New Shares pursuant to the Oversubscription

Facility.

The New Shares are of the same class as (and rank

equally with) Rua’s Existing Shares which are quoted on

the NZX Main Board. Rua will take any necessary steps to

ensure that the New Shares are, immediately after the

issue, quoted.

The Rights will be quoted on the NZX Main Board. Eligible

Shareholders may take up all or some or none of their

Rights. Eligible Shareholders may also sell all or some of

their Rights on the NZX Main Board between 28

September 2026 and 9 October 2026.

2. Issue Price

The Issue Price is $0.025 per New Share. The Issue Price

must be paid in full by 5:00pm on the Closing Date (being

15 October 2026, unless extended). Rua may accept late

applications and payment of application monies in its

sole discretion, but has no obligation to do so.

Rua may also accept or reject (at its discretion) any online

application which it considers is not completed correctly,

and/or may correct any errors or omissions on any online

application.

If an Eligible Shareholder fails to take up its Entitlement by

applying for any New Shares and paying the application

monies for those New Shares by the Closing Date

(5:00pm on 15 October 2026, unless extended), that

Eligible Shareholder’s Rights will lapse.

As required by the Listing Rules, if Rua receives, before

the Closing Date, a renunciation and an acceptance in

respect of the same Right(s), the renunciation shall be

given priority to the acceptance.

All application monies received will be held in a trust

account with Computershare until the corresponding

New Shares are allotted or the application monies are

refunded. Interest earned on the application monies will

be for the benefit, and remain the property, of Rua and will

be retained by Rua whether or not the issue of New

Shares takes place. Any refunds of application monies

will be made within 5 Business Days of the issue of New

Shares (or such earlier date that the decision not to

proceed with the Offer is made).

3. Eligibility

The Offer is only open to Eligible Shareholders, being

those persons with registered addresses in the Offer

Jurisdictions (or as Rua may otherwise determine in

compliance with applicable laws), who are registered as

Shareholders at the Record Date.

The Rights of any shareholder that is not an Eligible

Shareholder will be transferred to a nominee who will

endeavour to sell those Rights on the NZX Main Board.

Any proceeds (less transaction costs) will be paid to

those shareholders that are not Eligible Shareholders on a

pro rata basis.

4. Oversubscription Facility

Eligible Shareholders who accept their full Entitlement

may also apply for Additional New Shares (in excess of

their Entitlement) at the Issue Price pursuant to the

Oversubscription Facility.

Eligible Shareholders may apply for any number of

Additional New Shares, but there is no guarantee that

they will be allocated any or all of the Additional New

Shares for which they apply.

No applicant for Additional New Shares will be allocated

any greater number of Additional New Shares than the

number for which they have applied and paid.

Rua may scale applications under the Oversubscription

Facility in such manner as the directors of Rua consider

equitable and in the interests of the company.

In particular, for the purposes of the ASIC Corporations

(Foreign Rights Issues) Instrument 2015/356, Australian

residents cannot be allocated Additional New Shares

pursuant to the Oversubscription Facility to the extent

such allocation would result in more than 10% of the

maximum number of New Shares being offered to

Australian residents.

The Rua directors’ decision on scaling will be final.

If you are a Custodian, or hold your Shares through a

Custodian, please see paragraphs 13 and 14 below.



5. Opening and Closing Dates

The Offer will open for receipt of acceptances at 2:00pm
on 30 September 2026 (the “Opening Date”). The last day

for receipt of applications with payment is 5:00pm on 15

October 2026 (the “Closing Date”), subject to Rua

varying or extending those dates as permitted by and in

accordance with applicable laws and the Listing Rules.

6. Issue of New Shares

New Shares are expected to be allotted and issued on 21

October 2026 (the “Issue Date”).

In the event that the Closing Date for the Offer is

extended, Rua reserves the right to issue New Shares on

or about 21 October 2026, and weekly thereafter as any

further applications are received, until the date up to 5

Business Days after any extended Closing Date.

Statements for New Shares will be issued and mailed in

accordance with the Listing Rules.

7. Terms and ranking of New Shares

New Shares allotted and issued will be fully paid and will

be the same class as (and rank equally in all respects

with) the Existing Shares which are quoted on the NZX

Main Board on the Issue Date. They will give the holder the

right to one vote on a resolution at a meeting of

shareholders (subject to any restrictions in Rua’s

constitution or the Listing Rules), the rights to dividends

authorised by Rua’s board of directors and the right to a

proportionate share in any distribution of surplus assets

of Rua on any liquidation.

8. Partial acceptance

If you are an Eligible Shareholder, you are not required to

subscribe for all of the New Shares to which you would be

entitled under the Offer. You may subscribe for a

proportion of your New Shares or allow your entire

Entitlement to lapse.

9. Minimum amount raised

There is no minimum amount that must be raised for the

Offer to proceed.

10. NZX Main Board quotation

The New Shares will be quoted on the NZX Main Board

upon completion of allotment procedures. The NZX Main

Board is a licensed market operated by NZX, which is a

licensed market operator regulated under the FMCA.

NZX accepts no responsibility for any statement in this

document.

11. Rights Trading

Application has been made for permission to quote the

Rights on the NZX Main Board and all NZX requirements

have been duly complied with. However, NZX accepts no

responsibility for any statement in this document.

Eligible Shareholders may sell all or some of their Rights

on the NZX Main Board between 28 September 2026 and

9 October 2026. If you are not an NZX Shareholder and

you wish to trade your Rights on the NZX Main Board,

please contact your broker or an NZX Firm.

The right to apply for Additional New Shares under the

Oversubscription Facility is available to Eligible

Shareholders who take up their Rights in full only.

Investors who acquire Rights on the NZX Main Board and

are not Eligible Shareholders on the Record Date are not

entitled to apply for Additional New Shares under the

Oversubscription Facility.

Investors who acquire Rights on the NZX Main Board or

otherwise will, by acquiring those Rights, and applying to

take up all or part of those Rights, be deemed to agree to

make and be subject to the representations, declarations,

warranties and agreements on the website.

Investors should note that if they purchase Rights in a

transaction on the NZX Main Board or otherwise, in order

to take up or exercise those Rights and subscribe for New

Shares they:

• must be:

o located in/with a registered address in New

Zealand or Australia (including, for the

avoidance of doubt, Eligible Shareholders); or

o any other person to whom Rua consider an offer

of Rights or New Shares may be made without

the need for a lodged prospectus or other

formality (other than a formality with which Rua

is willing to comply); and

• must not be in the United States or acting for the

account or benefit of a person in the United States in

respect of the purchase or exercise of such Rights

and the subscription for New Shares. The Rights may

not be purchased, traded, taken up or exercised by

any person in the United States or by any person

acting for the account or benefit of a person in the

United States (to the extent such persons are acting

for the account or benefit of persons in the United

States).

If an investor does not satisfy the above conditions, they

will not be entitled to take up Rights or subscribe for New

Shares. It is the responsibility of purchasers of Rights to

inform themselves of the eligibility criteria to exercise the

Rights. If holders of Rights after the end of the Rights

trading period do not meet the eligibility criteria, they will

not be able to exercise the Rights. In the event that

holders are not able to take up their Rights, those Rights

will form part of the shortfall to be offered to new
investors, and holders may receive no value for them.

12. NZX Listing Rules

The issue of New Shares under the Offer is being

undertaken under NZX Listing Rule 4.3.1(a) (Pro-rata

issues) and 4.4 (Rules applicable to pro-rata issues).

In addition, the directors of Rua plan to place any shortfall

in the Offer with new investors, at the Issue Price, in

accordance with Listing Rule 4.4.

13. Custodians

In order to participate in the Offer on behalf of one or

more beneficial owners, Custodians must provide the

following information by email to Computershare and

make payment by way of electronic funds transfer:

a) the number of Participating Beneficiaries (as defined

in paragraph 14 below) and their names and

addresses;

b) in respect of each of the Participating Beneficiaries,

the number of Existing Shares that the Participating

Beneficiary holds and the number and dollar amount

of Rights, as well as the Additional New Shares the

Participating Beneficiary has instructed the

Custodian, either directly or indirectly through a

Downstream Custodian (as defined in paragraph 14

below), to apply for on behalf of that Participating

Beneficiary;

c) where the Custodian holds Existing Shares on behalf

of a Participating Beneficiary indirectly, through one

or more Downstream Custodians, the name and

address of each Downstream Custodian; and

d) an acknowledgement that the certifications

described in paragraph 14 below are deemed to have

been provided to Rua.

14. Custodian certifications

If a Custodian applies in the manner described above to

purchase New Shares on behalf of one or more beneficial

owners, the Custodian will be deemed to have certified to

Rua that:

a) the Custodian holds Existing Shares on behalf of:

i) one or more other persons that are not

Custodians (who would be Eligible

Shareholders if they held Existing Shares

directly); and/or

ii) another Custodian (Downstream Custodian)

that holds beneficial interests in Existing Shares

on behalf of one or more other persons to which

those interests relate, on the Record Date,

(each a Participating Beneficiary) who have

subsequently instructed the Custodian, and/or

the Downstream Custodian, to participate in

the Offer on their behalf;

b) the information set out in the email required to be

provided to Computershare under paragraph 13

above is true and accurate;

c) a copy of this document and the Investor

Presentation was given to each Participating

Beneficiary; and

d) the beneficial owner on whose behalf the Custodian

is submitting an application for New Shares is not

making an application as an Eligible Shareholder

under the Offer in respect of the Existing Shares held

by the Custodian on behalf of that beneficial owner,

and no other Custodian is submitting an application

for New Shares under the Offer for that beneficial

owner in respect of those Existing Shares.

Rua is not required to determine whether or not any

Eligible Shareholder is acting as a Custodian, or the

identity or residence of any beneficial owners of Shares.

Where any holder is acting as a Custodian for a foreign

person, that holder, in dealing with its beneficiary, will

need to assess whether indirect participation by the

beneficiary in the Offer is compatible with applicable

foreign laws. Eligible Shareholders who are Custodians

are therefore advised to seek independent advice as to

how to proceed.

For the avoidance of doubt, each Custodian is

responsible for determining whether an underlying

beneficial holder of Existing Shares for whom that

Custodian acts as Custodian is an Eligible Shareholder.

If you hold your Shares through a Custodian, please

provide your Custodian with your instructions so that your

Custodian may apply on your behalf in accordance with

the information above.

15. Amendments to the Offer and waiver of

compliance

Notwithstanding any other term or condition of the Offer,

Rua may, at its discretion and to the maximum extent

permitted by law:

a) make non-material modifications to the Offer on

such terms and conditions as it thinks fit (in which

event applications for New Shares under the Offer

will remain binding on the applicant notwithstanding

such modification and irrespective of whether an

application was received by the Computershare

before or after such modification is made); and/or

b) suspend or terminate the Offer at any time prior to

the issue of the New Shares under the Offer

(including by reviewing the timetable for the Offer).

If the Offer is terminated, application monies will be
refunded to applicants without interest within 5 Business

Days of termination.

Rua reserves the right to waive compliance by any

applicant under the Offer with any provision of these

terms and conditions.

Rua will notify NZX of any waiver, amendment, variation,

suspension, withdrawal or termination of the Offer.

16. Governing law

These terms and conditions shall be governed by and

construed in accordance with the laws of New Zealand.

17. Other disclosures

Investors are encouraged to review the Rua audited

financial statements for the 12-month period ended 30

June 2026. The audited financial statements are included

in the 2026 Annual Report (at

www.nzx.com/companies/RUA/announcements)

Investors should also consider the factors discussed in

Rua’s Investor Presentation dated 22 September 2026

which includes details of the rationale and risks relating

to the Offer.

Other announcements about Rua, including any

announcement made after the date of this document, are

available and can be accessed at www.nzx.com under

the ticker code “RUA”.

Glossary
2026 Annual Report means Rua’s annual report for the year ended 30 June 2026.

Additional New Shares means New Shares which an Eligible Shareholder applies for over and above their Entitlement

under the Oversubscription Facility.

Business Day has the meaning given to that term in the Listing Rules.

Computershare means Computershare Investor Services Limited.

Closing Date means 5:00pm on 15 October 2026 (unless extended beforehand by notice in writing to NZX).

Custodian means any Eligible Shareholder that:

a. is a trustee corporation or a nominee company and holds Existing Shares on the Record Date by reason only of

acting for another person in the ordinary course of business of that trustee corporation or nominee company; or

b. holds Existing Shares by reason only of being a bare trustee of a trust to which the Existing Shares are subject.

Eligible Shareholders means a Shareholder with a registered address in the Offer Jurisdictions, as at the Record Date.

Entitlement means the number of Rights to which an Eligible Shareholder is entitled.

Existing Shares means a Share in Rua on issue on the Record Date.

FMCA means the Financial Markets Conduct Act 2013.

Rua means Rua Bioscience Limited (New Zealand company no. 6484092 with NZX ticker code: RUA).

Investor Presentation means the investor presentation relating to the Offer which was released by Rua on 22

September 2026.

Ineligible Shareholder A Shareholder other than an Eligible Shareholder.

Issue Date means 21 October 2026.

Issue Price means $0.025 per New Share.

Listing Rules means the NZX listing rules, as amended from time to time and for so long as Rua is listed by NZX.

New Shares means an ordinary share in Rua, being of the same class as, and ranking equally in all respects with, the

Existing Shares at the time of issue of the New Shares.

NZX means NZX Limited.

NZX Firm means any entity designated as an NZX Firm under the Participant Rules of NZX.

NZX Main Board means the main board equity security market operated by NZX.

Offer means the offer to subscribe for New Shares made to Eligible Shareholders pursuant to this document.

Offer Jurisdictions means New Zealand, Australia or such other places where a shareholder satisfies Rua that the

Offer can lawfully be made and accepted. However, Shareholders in the United States are not eligible to participate in

the Offer. Similarly, Shareholders (including trustees, Custodians and nominees) who hold Shares on behalf of persons

in the United States, or are acting for the account or benefit of persons in the United States, are not eligible to

participate in the Offer on behalf of those persons.

Opening Date means 30 September 2026.

Oversubscription Facility means the facility that entitles an Eligible Shareholder who accepts their Entitlement in full

to also apply for Additional New Shares.

Record Date means 5pm 29 September 2026.

Renounceable means an Eligible Shareholder can sell or otherwise transfer its Rights (which are quoted) to a third
party (whether or not an existing Shareholder) who can use those Rights to buy the New Shares that the Eligible

Shareholder is otherwise entitled to.

Rights means the renounceable right to subscribe for one New Share at the Issue Price, issued pursuant to the Offer.

Share means one ordinary fully paid share in Rua.

Shareholder means a registered holder of Shares.

Takeovers Code means the takeovers code set out in the schedule to the Takeovers Regulations 2000.

All references to time are to New Zealand time, references to currency are to New Zealand dollars, and any references

to legislation are references to New Zealand legislation unless stated or defined otherwise.



Directory
Issuer

Rua Bioscience Limited

PO Box 1387

Gisborne 4040

Aotearoa New Zealand


Legal Adviser


Lowndes Jordan

Level 15, HSBC Tower

188 Quay Street, Auckland CBD

Auckland 1010


Registrar


Computershare Investor Services Limited

Level 2, 159 Hurstmere Road

Ta k a p u n a

Auckland 0622

New Zealand


Telephone: +64 9 488 8793

Freephone: 0800 650 034

Website: www.shareoffer.co.nz/rua

Email: rua@computershare.co.nz

---

Investor Presentation
22 September 2026

This presentation contains summary information about Rua Bioscience Limited (Rua) and its activities that is current as at the date of this presentation.
Information of a general nature

The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Rua or that would be required in a

product disclosure statement for the purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or a prospectus orother disclosure document for the purposes of the laws of any other jurisdiction. Rua is subject to a disclosure obligation

that requires it to notify certain material information to NZX Limited (NZX) for the purpose of that information being made available to participants in the market and that information can be found by visiting www.nzx.com/companies/rua

. This

presentation should be read in conjunction with Rua's other periodic and continuous disclosure announcements released to NZX.

Proposed Offer

This presentation has been prepared by Rua in relation to a proposed offer of new ordinary shares in Rua (Shares) by way of a renounceable entitlement offer (Offer). Notwithstanding the proposed Offer, this presentation is for information purposes only

and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Rua reserves the right not to proceed with the Offer, to vary the dates of the Offer or to withdraw the Offer without prior notice.No information set out in

this presentation will form the basis of any contract.

Not financial product advice

This presentation does not constitute legal, financial, tax, financial product advice or investment advice or a recommendation to acquire Rua securities, and has been prepared without taking into account the objectives, financial situation or needs of

investors. Before making an investment decision, prospective investors should consider the appropriateness of the informationhaving regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or

other professional advisor if necessary.

Forward-looking statements

This presentation may contain forward-looking statements that reflect Rua’s current views with respect to future events. This includes statements regarding the timetable, conduct and outcome of the Offer and the use of proceeds thereof, statements

about the plans, objectives and strategies of the management of Rua, statements about the industry and the markets in which Rua operates, and statements about the future performance of, and outlook for, Rua’s business. Any indications of, or guidance

or outlook on, future earnings or financial position or performance are also forward-looking statements. All such forward-looking statements, by their very nature, involve inherent known and unknown risks, significant uncertainties, assumptions,

contingencies, and other factors, many of which are outside the control of Rua, are difficult to predict, and which could causeactual results or performance of Rua to materially differ from any future results or performance expressed or implied by such

forward looking statements. Variations could either be materially positive or materially negative. The information is stated only as at the date of this presentation. Except as required by law or regulation (including the NZX Listing Rules), Rua undertakes

no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To the maximum extent permitted by law, the directors of Rua, Rua and any of its related bodies corporate and affiliates,

and their respective officers, partners, employees, agents, associates and advisers do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of such information, or the likelihood of fulfilment of any

forward-looking statement or any event or results expressed or implied in any forward-looking statement, and disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).

Any estimates or projections as to events that may occur in the future (including any projections of revenue, capacity, earningsand performance) are based upon the best judgement of Rua from the information available as of the date of this presentation.

A number of factors could cause actual results or performance to vary materially from the projections, including the risk factors set out in this presentation. Investors should consider the forward-looking statements in this presentation in light of those risks

and disclosures.

Investors are strongly cautioned not to place undue reliance on any forward-looking statements.

Financial data

All dollar values are in New Zealand dollars unless otherwise stated.

This presentation should be read in conjunction with, and subject to, the explanations and views of future outlook on market conditions, earnings and activities given in the announcements relating to the audited financial results for the year ended 30

June 2026.

Effect of rounding

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject tothe effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

Disclaimer and important notice 1 of 2

Pastperformance
Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of(a nd provides no guidance as to) future Rua performance, including future financial position or share price performance. Past performance

information provided in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) a promise, representation, warranty or guarantee as to the past, present or future performance of Rua.

Investment risk

An investment in securities of Rua is subject to investment risk and other known and unknown risks, some of which are beyond thecontrol of Rua. Rua does not guarantee any particular return or the performance of Rua shares.

Not an offer

This presentation is not a prospectus or product disclosure statement or other offering document under New Zealand or Australianlaw or any other law (and will not be filed with or approved by any regulatory authority in New Zealand, Australia or any other

jurisdiction). This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Any decision to purchase Shares in the Offer must be made on the basis of all information provided in

relation to the Offer, including information to be contained or referred to in a separate offer document made available on NZX (Offer Document) and Rua’s other periodic and continuous disclosure announcements released to NZX. Any eligible shareholder who wishes

to participate in the Offer should consider the Offer Document, in addition to Rua’s other periodic and continuous disclosureannouncements released to NZX, in deciding to apply under the Offer. Anyone who wishes to apply for Shares under the Offer willneed to

apply in accordance with the instructions contained in the Offer Document and the application form. The distribution of this presentation outside New Zealand or Australia may be restricted by law. Any recipient of this presentation who is outside New Zealand or

Australia must seek advice on and observe any such restrictions.

Distribution of presentation

This presentation may not be reproduced in any form or further distributed to any other person, passed on, directly or indirectly, to other person, or published, in whole or in part, for any purpose. Additionally, this presentation must not be distributed in any

jurisdiction outside New Zealand and Australia in circumstances in which the distribution of this presentation would be unlawful. The distribution of this presentation in jurisdictions outside New Zealand and Australia may be restricted by law, and personsinto whose

possession this presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of Rua, any person named in this presentation or any of their affiliates accept or shall haveany liability to

any person in relation to the distribution or possession of this presentation from or in any jurisdiction.

No offer in the United States

This presentation is not for distribution or release in the United States. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Any shares described in this presentation have not been, and will not

be, registered under the US Securities Act of 1933, as amended, or the securities laws of any state or other jurisdiction of theUnited States, and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the

US Securities Act of 1933, as amended, and applicable US state securities laws.

Disclaimer

None of Rua or Rua's advisers (including the lead manager for any offer of Rua securities) or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorised, permitted or caused the issue,submission,

dispatch or provision of this presentation and, except to the extent referred to in this presentation, none of them makes or purports to make any statement in this presentation and there is no statement in this presentation which is based on any statement by any of

them.

To the maximum extent permitted by law, none of Rua and its advisers (including the lead manager for any offer of Rua securities), affiliates, related bodies corporate, nor their respective directors, officers, partners, employees and agents (Specified Persons) makes any

representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in thispresentation and none of them shall have any liability (including in tort or for negligence) for:

-any errors or omissions in this presentation; or

-any failure to correct or update this presentation, or any other written or oral communications provided in relation to this presentation; or

-any claim, loss or damage (whether foreseeable or not) arising from the use of any information in, or omitted from, this presentation or otherwise arising in connection with this presentation or the information contained in, or omitted from, it.

To the maximum extent permitted by law, you agree that you will not bring any proceedings against or hold or purport to hold anySpecified Person liable in any respect for this presentation or the information in this presentation and waive any rights youmay otherwise

have in this respect.

Acceptance

By reading this presentation, you agree to be bound by the foregoing limitations and restrictions and. in particular, will bedeemed to have represented, warranted, undertaken and agreed that: (i) you have read and agree to comply with the contents of this Disclaimer

and Important Notice; (ii) you are permitted under applicable laws and regulations to receive the information contained in this presentation; (iii) you will base any investment decision solely on information released by Rua via NZX (including the Offer Document); and

(iv) you agree that this presentation may not be reproduced in any form or further distributed to any other person, passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Disclaimer and important notice 2 of 2

Kia ora, and thank you
A note from the Chair and Chief Executive

•Last year we asked for your support to take Rua through a pivotal stage of growth. You supported us, and that

support has helped us build the platform we have today.

•Much has changed over the past 12 months. Revenue has grown, our capital-light model is demonstrating

improved operating leverage, and Rua is now selling into five medicinal cannabis markets.

•Most importantly, customers are demonstrating their confidence in Rua's products and capabilities. Our largest

export agreement to date with a clinic chain in the United Kingdom is a significant example of that progress.

•The strategy is producing commercial evidence, but we need further capital to fulfil and scale the opportunities

before us. Rua is seeking to raise up to $2.8m through a pro-rata rights offer.

•The capital will fund this growth through mainly inventory for international markets, in particular the UK.

•The company continues to explore all options for the sale of the Gisborne manufacturing facility in order to free up

capital, and also to reduce operating expenditure further.

•Rua has secured a further $0.3m of existing convertible notes will convert to equity at the offer price if the offer

raises a minimum of $1.5m.

Same kaupapa, stronger evidence
We remain focused on our strategy

•A capital-light model anchored in genetics and distribution, not cultivation or manufacturing infrastructure.

•Outsourcing commercial manufacturing has helped cut operating expenditure as revenue increases.

•New distribution and offtake agreements extend our reach without adding capital cost.

•The model is working: we are converting our genetics, partnerships and market access into growing international

sales

5

Revenue NZ$m

71%

Customer Revenue

Growth Year-on Year

International

markets

0.3

1.9

2.9

FY24FY25FY26

01
Our Strategy

Genetics and mātauranga at the core
Our community links is our point of difference

•Our edge starts with genetics selected in Te Tairāwhiti- cannabinoid and terpene profiles unique to Rua.

•We work with legacy growers, and we're proud of those connections - access to varieties available nowhere else.

•Genetics travel efficiently. Clones, licences and seed can move around the world with significantly less cost and

complexity than finished product - this is what makes our capital-light model possible.

•Our knowledge of controlled drugs allows us to work with psilocybin with the Tu Wairua collaboration to treat

methamphetamine addiction.

8
Germany | Australia

New Zealand | United

KingdomCzechia

Rua is doing medicinal cannabis differently in the NZ market

Unique Genetics

Rua’s point of difference

Rua has outsourced production to best-in-class global cultivation and manufacturing

partners. This provides access to significantly higher capacity which is close to

market and at a lower per unit cost, while avoiding the high capital costs of GMP

manufacturing.

Rua operates in a targeted segment of the market with the lowest capital requirements. This

means we can leverage our expertise to deliver scalable value with trusted partners.

From genetics to global markets
How genetics become revenue

•Clones exported live -Canada

•Licensed and grown out - Aotearoa, Canada

•Finished product via distribution partners –Germany, United

Kingdom, Australia

•Agreements established - Portugal

Six markets, one platform

•Aotearoa, New Zealand -our home market

•Australia - second-largest medicinal cannabis market

globally

•Germany - world's largest medicinal cannabis market

•United Kingdom -fastest-growing market

•Czechia - a new foothold, early growth

•Canada - a new genetic pool, first live clone exports

02
Investment Highlights

Evidence across six markets
The strategy is translating into commercial activity across established and new markets.

AUSTRALIA

Revenue almost doubled

Strong clinic relationships continue to

support our position in one of the world’s

most competitive markets.

UNITED KINGDOM

~NZ$10m expected (over 2yrs)

Largest export agreement to date; a

major customer commitment that

provides clear evidence of demand.

AOTEAROA NZ

Share and revenue up

New medical device launched and five

further product approvals received.

GERMANY

Delivered cost ↓ ~50%

Supplier renegotiation has materially

improved economics following a

regulatory reviewperiod and a year of

tough trading environment.

CZECHIA

First revenues booked

An early foothold in a market with room

to grow.

CANADA

First live clone export

Demonstrates how Rua’s genetics

platform can open further markets

without owned infrastructure.

The important point: progress is not dependent on a single market or contract.

Rua today: the strategy is producing commercial evidence
The business has moved from building the platform to demonstrating that the platform works, on a fixed cost base.

$2.9m

FY26 revenue

up 54% year-on-year

+71%

Customer revenue

growth

FY25 to FY26

3% ↓

Opex

Year-on-Year

5

International cannabis

markets

established commercial

pipelines

~NZ$10m

UK agreement

anticipated revenue over two

years

GENETICS

Te Tairāwhiti

PARTNERS

Capital-light

DISTRIBUTION

6 markets

CUSTOMERS

Demand

REVENUE

$2.9m

This is a commercial business with increasing demand. The largest constraint is working capital, not infrastructure.

Largest export supply agreement to date
Commercial validation of our strategy

~$NZ10m

anticipated revenue

over an initial two-year period

assuming Rua can fund the necessary

working capital

MAJOR UK CLINICAL CUSTOMER

Promoting and selling Rua products into

the UK market

Why this matters

New Zealand-grown

product

→

NZ growers + partners

→

UK distribution

The commercial model is already in place

SUPPLY

NZ growers in place

SCALE

Additional growers required

DEMAND

Customer commitment secured

The UK agreement is evidence that the strategy is working and not an

aspiration for the future.

The opportunity now is to supply anticipated demand.

Three research programmes, all rooted in Te Tairāwhiti
Rua is already working with partners on the next generation of botanical products.

19

Wairuakohu Project

Radula liverwort

A liverwort native to Aotearoa that produces

compounds understood to act on the same

receptors as cannabinoids. Rua is partnering with

researchers on its potential.

WairuakohuCharitable Trust, NZ Institute for Bioeconomy

Science, IO Limited

Tū Wairua Project

Psilocybin-containing mushrooms

Rua is contributing specialist cultivation and

regulatory capability to the TūWairua research

collaboration, led by the Rangiwaho Marae

community.

RangiwahoMarae, ESR, Uni of Auckland, Uni of Waikato,

Matai Medical Research, NZ Institute for Bioeconomy

Science

Cytisine from kōwhai

A native source of an established medicine

Cytisine, an alkaloid found in kōwhai, is a long-

established smoking-cessation medicine with a

substantial clinical evidence base, including New

Zealand-led trials.

IO Limited,

To be clear: no revenue from these programmes is assumed in FY27 or FY28. They integrate with our existing business, with Rua contributingcapability, licensing and

access rather than capital.

The capability we built for cannabis is not limited to cannabis
Longer-term research using our core knowledge and experience.

18

Now

FY26 – FY28

Medicinal cannabis

Five markets, established distribution, unique genetics. This is the business, and it is where

every dollar of this offer goes.

~100% of revenue

Research

FY28 onward

Cytisine, Wairuakohu, and TūWairua psilocybin

Three research collaborations that draw on the same licensing, regulatory and supply

capability Rua already runs every day.

Nil assumed

Exploratory

FY27 onwards

Further natural ingredients from Te Tairāwhiti

Early scoping of other botanical and rongoā ingredients from our rohe, guided by

kaitiakitanga and benefit-sharing.

Nil assumed

Contribution to FY27 revenue

Integration with Rua: Controlled-drug licensing, regulatory expertise, GMP supply relationships, high-hygiene cultivation, export permitting, mātaurangaMāori

and community relationships. Rua provides a framework of knowledge to integrate with new products in the future.

16
Growing without losing our kaupapa

Through Rua‘s scholarship programme, assisting Te

Tairawhiti students through their studies, they have

positively impacted

67

Students since 2020

Student Scholarship ProgrammeCompassionate Access Programme

Leveraging support from partners and local

community, Rua are now supporting up to 52

patients each month by supplying medicinal

cannabis through their Compassionate Access

Programme.

86

Patients supported

since April 2022

03
Why We're Raising

We need further capital to grow our revenue
•Growth at this pace needs working capital -inventory has to be funded ahead of sales as we scale into

established international markets.

•We have funded that working capital requirement since our last raise through a disciplined mix of equity and debt.

To sustain the current growth trajectory and convert demand into revenue, further shareholder support is required.

•We have also taken action to reduce our cost base and unlock capital from the property portfolio. We have

consolidated operations into the Gisborne manufacturing facility, reducing operating costs while establishing the

property as a tenanted, income-generating asset. We continue to pursue options to realisevalue from the

property and redeploy capital into the business.

•The offer is about funding growth, not building infrastructure. It provides the working capital required to fulfil

existing contracted demand and convert an increasingly visible sales pipeline into revenue.

•This is the same capital-light model that underpins our strategy. We are not seeking significant infrastructure

investment to enter new markets; we are funding the working capital required to supply products into markets

where demand, distribution and commercial pathways are already established.

Capital converts demand into revenue
The capital raised will be used primarily to fund inventory and working capital ahead of confirmed and

anticipated sales growth.

Particularly to fulfil the UK agreement, meet growing demand in Australia and Aotearoa, New Zealand, and support market entry in

Canada and Czechia.

DEMAND

UK agreement + growing

demand

in Australia & Aotearoa, NZ

WORKING CAPITAL

Fund inventory

ahead of sales

FULFILMENT

Deliver customer orders

and support market entry

MARGIN GROWTH

Convert established demand

into realised revenue

The majority of capital will be used for growth.

04
The Offer

Offer Details
21

Offer Size and

Structure

•1 for 3 pro-rata renounceable entitlement offer to raise up to ~$2.8 million (if fully subscribed)

•Up to approximately 113.1m new Rua shares to be issued (33% of existing shares on issue)

•Offer structure similar to 2025 rights offer with shortfall shares available to new investors

Offer Terms

•$0.025 per new share, representing a discount of 32% to the 20-day volume weighted average price of

Rua shares traded on the NZX Main Board up to 17 September 2026

•The offer is renounceable meaning shareholders who choose not to take up their entitlements may sell

some or all of their rights on the NZX Main Board (subject to sufficient demand for the rights)

•Shareholders who subscribe for their entitlements in full may also subscribe for any number of additional

shares through the oversubscription facility

•Further terms of the rights offer can be found in the offer document dated 22 September 2026 and at the

offer website: www.shareoffer.co.nz/rua

Use of Proceeds

•All net proceeds from the offer will be used to fund Rua’s working capital requirements and ongoing

operating expenses

Ranking •New shares issued under the Offer will rank equally in all respects with Rua’s existing ordinary shares

Offer Timetable
22

Announcement of the OfferTuesday, 22 September 2026

Rights Trading Opens

(Rights trading commences on the NZX Main Board)

Monday, 28 September 2026

Record Date

(for determining eligibility to participate in the offer and entitlements)

5pm, Tuesday, 29 September 2026

Opening Date of the Offer

(including mailing/emailing of Offer documentation)

2pm, Wednesday, 30 September 2026

Rights Trading Closes

(Rights trading closes on the NZX Main Board at the close of trading)

Friday, 9 October 2026

Closing Date of the Offer

(being the date by which applications and payment must be received)

Thursday, 15 October 2026

Announcement of Results of the OfferTuesday, 20 October 2026

Issue Date

(for the allotment and issue of the new shares)

Wednesday, 21 October 2026

Quotation of New Shares on NZX Main BoardWednesday, 21 October 2026

Holding Statements DispatchedTuesday, 27 October 2026

---

Corporate Action Notice

Page 1 of 3


Section 1: Issuer information

Name of issuer Rua Bioscience Limited

Class of Financial Product Ordinary shares

NZX ticker code RUA

ISIN NZRUAE0004S1

Name of Registry Computershare Investor Services Limited

Type of corporate action

(Please mark with an X in the relevant

box/es)

Share Purchase

Plan/retail offer

Renounceable

Rights issue or

Accelerated

Offer

x

Capital

reconstruction

Non-

Renounceable

Rights issue or

Accelerated

Offer


Call Bonus issue

Placement

Record date Tuesday, 29/09/2026

Ex Date (one business day before the

Record Date)

Monday, 28/09/2026

Currency NZD

External approvals required before

offer can proceed on an unconditional

basis?

N

Details of approvals required N/A

Section 2: Rights Issue or Accelerated Offer

2a: Rights Issue (i.e. non-accelerated)

Maximum number of Equity Securities

to be issued if offer is fully subscribed

Approximately 113,147,235 (subject to rounding)

ISIN of Rights (if applicable) NZRUAE0007S4

Oversubscription facility Y. New shares not taken up by eligible shareholders in the

rights issue will be offered through an oversubscription

facility. Eligible shareholders who take up their rights in full

have the opportunity to apply for additional new shares in

the oversubscription facility.

Details of scaling arrangements for

oversubscriptions

If demand for New Shares were to exceed availability,

applicants participating in the Oversubscription Facility will

be subject to scaling on a pro rata basis (by reference to

existing holdings on the Record Date).

Rua reserves the right to place any subsequent shortfall in

accordance with the NZX Listing Rules.

2 of 3
Rights entitlement ratio (for example 1

Right issued for 3 existing shares

held)


Rights

Issued


1




For

Existing Shares

Held


3


Rights exercise ratio


1 Right will exercise to: 1 Ordinary Share

Number of Rights to be issued in the

Rights Issue

113,147,235

Treatment of fractions** Where fractions arise in the calculation of rights, they will

be rounded down to the nearest right

Subscription price

The price payable per equity security upon exercise

of rights to subscribe for new shares under the rights

issue

$0.025

Letters of entitlement mailed Wednesday, 30/09/2026

Offer open Wednesday, 30/09/2026

Offer close Thursday, 15/10/2026

Quotation date

1

(if Rights or

entitlements will be quoted)

Market open on:

Monday, 28/09/2026

Allotment date Market open on:

Wednesday, 21/10/2026

Section 8: Lead Manager and Underwriter

Lead Manager(s) appointed Y

Name of Lead Manager(s) Northington Partners Limited

Fees, commission or other

consideration payable to Lead

Manager(s) for acting as lead

manager(s)

Rua agrees to pay a lead management fee of 7.5% of the total

gross proceeds raised under the rights offer.

Underwritten N

Name of Underwriter(s) N/A

Extent of underwriting (i.e.

amount or proportion of the offer

that is underwritten)

N/A

Fees, commission or other

consideration payable to

Underwriter(s) for acting as

underwriter(s)

N/A

Summary of significant events

that could lead to the

underwriting being terminated

N/A


1

The Quotation date for Rights will usually be the Ex Date (Listing Rule 4.17.6(b)).

3 of 3
Section 9: Authority for this announcement

Name of person authorised to make

this announcement

Paul Naske

Contact person for this

announcement

Paul Naske

Contact phone number 021 445 154

Contact email address paul.naske@ruabio.com

Date of release through MAP 22/09/2026

---

CLEANSING STATEMENT


22 September 2026


NZX Limited

Wellington 6011

New Zealand


RUA BIOSCIENCE LIMITED (NZX: RUA): NOTICE PURSUANT TO CLAUSE 20(1)(a) OF

SCHEDULE 8 TO THE FINANCIAL MARKETS CONDUCT REGULATIONS 2014


1. Rua Bioscience Limited (NZX: Rua) (Rua) has today announced that it will undertake

a pro rata 1 for 3 renounceable rights offer of fully paid ordinary shares of the same

class as already quoted on the NZX Main Board operated by NZX Limited (

Rights

Offer) and may also seek to privately place any shortfall in the rights issue (Shortfall

Offer, and together with the Rights Offer, the Offers). The Company is seeking to

raise up to NZ$2,828,681 in connection with the Offers.

2. Offers made under the Rights Offer will be made to investors in New Zealand in

reliance upon the exclusion in clause 19 of Schedule 1 to the Financial Markets

Conduct Act 2013 (

FMCA). The Offers made under any Shortfall Offer will be made

to either

wholesale investors or close business associates (within the meaning of

clause 3(2) or clause 4(2), as applicable, of the FMCA), or to investors in New Zealand

in reliance upon the exclusion in clause 19 of Schedule 1 to the FMCA.

3. Offers under the Rights Offer are also being made to investors in Australia in reliance

on the Australian Securities and Investments Commission Corporations (Foreign

Rights Issues) Instrument 2015/356 or otherwise to persons to whom the Offers can

be made without a full disclosure document under Chapter 6D of the Corporations

Act 2001 (Cth).

4. This notice is provided pursuant to clause 20(1)(a) of Schedule 8 to the Financial

Markets Conduct Regulations 2014 (

FMC Regulations).

5. As at the date of this notice:

5.1. Rua is in compliance with the continuous disclosure obligations that apply to it

in relation to Rua’s quoted ordinary shares;

5.2. Rua is in compliance with its “financial reporting obligations” (as defined in

clause 20(5) of Schedule 8 to the FMC Regulations); and

5.3. there is no information that is “excluded information” (as defined in clause 20(5)
of Schedule 8 to the FMC Regulations) in respect of Rua.

6. The Offers are not expected to have any effect on the “control” (as defined in clause

48 of Schedule 1 to the FMCA) of Rua.


ENDS

The person who authorised this announcement:


Paul Naske

Chief Executive Officer

Paul.naske@ruabio.com

+64 21 445154

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.